Trial PaperDepressive DisordersMajor Depressive Disorder (MDD)Set & SettingEquity and EthicsPsilocybin

Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression

This qualitative study (n=28 interviews) of participants in a psilocybin-assisted therapy trial for cancer-related depression found that therapeutic benefits were closely tied to participants' ability to surrender (accepting and remaining open to the experience's intensity and unpredictability), with a safe, supportive, and ethical environment critical to fostering trust and engagement, and preparation and integration key to maximizing benefit, whilst music played a significant but variable role and ceremonial elements added meaning for many despite the clinical setting providing safety.

Authors

  • Manish Agrawal
  • Yvan Beaussant

Published

General Hospital Psychiatry
individual Study

Abstract

Background

Psilocybin-assisted therapy (PAT) shows promise for cancer-related depression, yet little research has examined how therapeutic context shapes patient experiences. While set (mindset) and setting (environment) are considered central to psychedelic treatment, empirical evidence on their role in PAT acceptability remains limited. This study explores factors influencing the acceptability of PAT from the perspective of patients with cancer and depression.

Methods

We conducted semi-structured interviews with participants in a clinical trial of psilocybin-assisted therapy. Using template analysis, we examined themes related to the acceptability of the experience and the surrounding therapeutic environment.

Results

Participants (n = 28) described the psilocybin experience as intense and demanding, with therapeutic benefits closely tied to their ability to “surrender”-a term used to describe accepting and remaining open to the experience's intensity and unpredictability. A safe, supportive, and ethical environment was critical in fostering trust and engagement. Preparation and integration were key to maximizing benefit. Music played a significant but variable role, sometimes enhancing and other times distracting. While the clinical setting provided safety, ceremonial elements added meaning for many.

Conclusions

Findings highlight how therapeutic structure, preparation, and setting shape PAT acceptability, supporting the need for patient-centered approaches to optimize care and outcomes.

Available with Blossom Pro

Research Summary of 'Set and setting in psilocybin-assisted therapy: A qualitative study of patients with cancer and depression'

Introduction

Interest in psychedelic-assisted therapy (PAT) has renewed attention to the non‑pharmacological elements that accompany drug administration, commonly framed as "set" (patients' mindset) and "setting" (the treatment environment). Earlier research and contemporary models suggest these contextual factors shape subjective experiences and hence therapeutic outcomes, but empirical, especially qualitative, investigations of how set and setting influence acceptability and patient experience in PAT are scarce. Debates persist about whether preparatory work, therapist presence, music, ritualised elements and integration practices are merely safety scaffolds or active contributors to efficacy. Beaussant and colleagues set out to explore how elements of therapeutic context shaped acceptability, perceived safety and therapeutic benefit among patients with cancer and major depressive disorder who participated in a Phase II open‑label psilocybin trial. Using semi‑structured exit interviews, the study examined participants' perspectives on preparation, dosing‑day environment, music, therapist support, and integration practices, aiming to generate empirical insights into the interplay between the psilocybin experience and its therapeutic container to inform optimisation of PAT delivery.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (14)

Papers cited by this study that are also in Blossom

Reactions to psilocybin administered in a supportive environment

Leary, T., Litwin, G. H., Metzner, R. · Journal of Nervous and Mental Disease (1977)

Constructing drug effects: a history of set and setting

Hartogsohn, I. · Drug Science Policy and Law (2017)

389 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder

Agrawal, M., Richards, B. D., Richards, W. A. et al. · Cancer (2023)

Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory

Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)

Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression

Murphy, R., Murphy-Beiner, A., Kettner, H. et al. · Frontiers in Pharmacology (2022)

162 cited
Experience of Music Used With Psychedelic Therapy: A Rapid Review and Implications

O'callaghan, C., Hubik, D. J., Psychiatry, M. et al. · Journal of Music Therapy (2020)

Show all 14 references
The hidden therapist: evidence for a central role of music in psychedelic therapy

Kaelen, M., Giribaldi, B., Raine, J. et al. · Psychopharmacology (2018)

213 cited
21 cited
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Vollenweider, F. X., Kometer, M. · Nature Reviews Neuroscience (2010)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.